FDA approval of HLB bile duct cancer drug sends Korea group stocks soaring

The FDA approved HLB's new drug Lifictu for bile duct cancer, driving significant stock price increases for HLB and related companies in South Korea. This marks the first time a domestic Korean corporation directly submitted a new drug application for a global anticancer drug to the FDA and secured approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 21 Sep 2026 and 28 Sep 2026.